NEW YORK (GenomeWeb News) – Cepheid today announced that Labsco has been named a US distribution partner for its GeneXpert Systems and tests.
Labsco has exclusive US distribution rights to sell the Cepheid products to acute care hospitals with less than 150 beds. The deal does not include Cepheid's higher-throughput GeneXpert Infinity System, the Sunnyvale, Calif.-based molecular diagnostics firm said.
Louisville, Ky.-based Labsco also has received non-exclusive rights to the non-acute care, non-hospital market, which would include surgical centers affiliated with hospitals, independent surgical centers, physicians' offices labs, group practices, and nursing homes.
"There are more than 3,900 US hospitals with less than 150 beds which have not been a primary focus of Cepheid to date," Nico Arnold, executive vice president of worldwide operations for Cepheid, said in a statement. "The decision to engage on a nationwide basis with Labsco is in line with one of our strategic growth objectives directed at expanding our reach within the US market."